| Name | Title | Contact Details |
|---|
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
CRI Worldwide is a Clementon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ScribeAmerica is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dak-Minn Blood Bank is a Grand Forks, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Pharma is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.